Aptar Q2 Sales, EPS Beat; Pharma Strength Offsets Beauty Margin Pressure
ATR sits 33% above its 52-week low of $103.227.
Summary
AptarGroup delivered a clean Q2 beat with sales of $1.03B (consensus $1.008B) and adjusted EPS of $1.42 (consensus $1.35), driven by consumer healthcare and injectables. Pharma segment growth was partly offset by lower emergency medicine sales, while Beauty margins dipped on mix and resin costs. The company repurchased $50M in shares during the quarter and reiterated Q3 adjusted EPS guidance of $1.45-$1.53, first issued earlier today. The emergency medicine destocking headwind is expected to fade by Q4, setting up a potential second-half recovery. With shares at $137 and a $158 median target, the beat and buyback signal management confidence.
At the time of this announcement, ATR was trading at $137.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $103.23 to $158.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.